Shalby Share Price

A fair growth of 5.23% in the revenue at Rs. 1779.44 millions was reported in the September 2022 quarter as compared to Rs. 1690.96 millions during year-ago period.A comparatively good net profit growth of 30.92% to Rs. 218.04 millions was reported for the quarter ended September 2022 compared to Rs. 166.54 millions of previous same quarter.Operating profit surged to 437.01 millions from the corresponding previous quarter of 345.23 millions.

The Revenue for the quarter ended  September 2022 of Rs. 1779.44 millions grew by 5.23 % from Rs. 1690.96 millions.A comparatively good net profit growth of 30.92% to Rs. 218.04 millions was reported for the quarter ended September 2022 compared to Rs. 166.54 millions of previous same quarter.Operating Profit saw a handsome growth to 437.01 millions from 345.23 millions in the quarter ended September 2022.

A fair growth of 17.20% in the revenue at Rs. 1760.18 millions was reported in the December 2022 quarter as compared to Rs. 1501.85 millions during year-ago period.Profit after tax for the quarter ended December 2022 reported a huge growth of 52.04% to Rs. 191.95  millions from Rs. 126.25 millions.Operating Profit saw a handsome growth to 385.57 millions from 312.48 millions in the quarter ended December 2022.

A fair growth of 17.20% in the revenue at Rs. 1760.18 millions was reported in the December 2022 quarter as compared to Rs. 1501.85 millions during year-ago period.Profit for the quarter ended December 2022 rises by 52.04% to Rs. 191.95  millions from Rs. 126.25 millions.Operating Profit saw a handsome growth to 385.57 millions from 312.48 millions in the quarter ended December 2022.

A fair growth of 17.20% in the revenue at Rs. 1760.18 millions was reported in the December 2022 quarter as compared to Rs. 1501.85 millions during year-ago period.Profit for the quarter ended December 2022 rises by 52.04% to Rs. 191.95  millions from Rs. 126.25 millions.Operating Profit saw a handsome growth to 385.57 millions from 312.48 millions in the quarter ended December 2022.

Pursuant to the provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Shalby has informed that the Board of Directors of the Company at the meeting held on October 18, 2022, which commenced at 4:00 pm and concluded at 5:35 pm, have considered and approved the following: Appointment of Vijay Kedia (DIN: 00230480) as an Additional Director (Non‐Executive Non‐ Independent) with effect from October 18, 2022, subject to approval of members of the Company. The details for appointment of above directors, as required under Regulation 30(6) read with Schedule III Part A para-A (7) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI circular CIR/CFD/CMD/4/2015 dated September 9, 2015 have been provided in Annexure – A.  

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 47(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, Shalby has informed that it enclosed the copies of advertisement published on November 09, 2022 in Financial Express (English and Gujarati edition) relating to dispatch of Notice of Postal Ballot including details of remote e-voting.

The above information is a part of company’s filings submitted to BSE.

Now, SGT can import the said implants and medical devices from USA and sell in Indonesia

Shalby is currently trading at Rs. 138.50, up by 2.45 points or 1.80% from its previous closing of Rs. 136.05 on the BSE.

The scrip opened at Rs. 139.00 and has touched a high and low of Rs. 142.75 and Rs. 138.25 respectively. So far 6185 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 167.95 on 09-Jan-2023 and a 52 week low of Rs. 95.10 on 23-Jun-2022.

Last one week high and low of the scrip stood at Rs. 145.95 and Rs. 135.15 respectively. The current market cap of the company is Rs. 1501.34 crore.

The promoters holding in the company stood at 74.12%, while Institutions and Non-Institutions held 4.03% and 21.85% respectively.

Shalby’s step‐down subsidiary -- Shalby Global Technologies, Singapore (SGT) has received a regulatory approval to market and sell Knee Implants, Hip Systems, Knee and Hip Instruments, etc. by Ministry of Health, Indonesia. Now, SGT can import the said implants and medical devices from USA and sell in Indonesia.

This development is fully in line with company’s stated strategy to grow company’s Orthopaedic implant business and establish footprint in the Medical device market internationally. This is a big milestone achieved by the Shalby group in its journey to serve many more international patients. The synergies between the businesses are compelling and will bring in immediate benefits of sourcing US FDA approved quality implants into Indonesia through company’s distribution channels. Shalby has performed more than 1,44,000 joint replacement surgeries so far and continues to be the leader in India and globally in terms of the volume of surgeries performed annually.

Shalby is a chain of Multi-specialty tertiary care hospitals based out of Ahmedabad. It has combined bed strength of more than 700 beds with its multispecialty hospitals across Gujarat and Goa.

This will be a customized program for healthcare professionals aspiring to become CXOs in the Hospital Industry

Shalby is currently trading at Rs.139.50, up by 1.95 points or 1.42% from its previous closing of Rs. 137.55 on the BSE.

The scrip opened at Rs. 137.20 and has touched a high and low of Rs. 138.75 and Rs. 137.20 respectively. So far 3300 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 167.95 on 09-Jan-2023 and a 52 week low of Rs. 95.10 on 23-Jun-2022.

Last one week high and low of the scrip stood at Rs. 142.75 and Rs. 135.15 respectively. The current market cap of the company is Rs. 1488.91 crore.

The promoters holding in the company stood at 74.12%, while Institutions and Non-Institutions held 4.03% and 21.85% respectively.

Shalby Academy, the healthcare education division of Shalby, has signed a memorandum of understanding (MoU) with the Indian Institute of Public Health University (IIPH), Gandhinagar, Gujarat to jointly develop and run a one‐year Advance Management Program in Hospital Leadership, for capacity building of Healthcare Professionals in the India and abroad using the LMS platform of the University & Shalby Academy.

The Program will be offered via online and campus immersion modes with a focus on emerging challenges in hospital & healthcare management leveraging the strength of both parties. This will be a customized program for healthcare professionals aspiring to become CXOs in the Hospital Industry.

Shalby is a chain of Multi-specialty tertiary care hospitals based out of Ahmedabad. It has combined bed strength of more than 700 beds with its multispecialty hospitals across Gujarat and Goa.

In accordance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, Shalby has informed that the Company will be virtually meeting with representatives of Rockstud Capital today on Tuesday, February 28, 2023. 

The above information is a part of company’s filings submitted to BSE.

The company has signed MoU to jointly develop various vocational undergraduate & post Graduate courses in allied health science

Shalby is currently trading at Rs. 133.80, up by 3.15 points or 2.41% from its previous closing of Rs. 130.65 on the BSE.

The scrip opened at Rs. 130.00 and has touched a high and low of Rs. 134.75 and Rs. 128.75 respectively. So far 7985 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 167.95 on 09-Jan-2023 and a 52 week low of Rs. 95.10 on 23-Jun-2022.

Last one week high and low of the scrip stood at Rs. 134.75 and Rs. 126.45 respectively. The current market cap of the company is Rs. 1447.33 crore.

The promoters holding in the company stood at 74.12%, while Institutions and Non-Institutions held 4.03% and 21.85% respectively.

Shalby’s healthcare education division -- Shalby Academy has signed Memorandum of understanding (MoU) with Silver Oak University, Ahmedabad to jointly develop various vocational undergraduate & post Graduate courses in allied health science like Radio imaging, Operation Theater & Medical Laboratory Technology.

As a skill knowledge partner, Shalby Academy will conduct these programs on a full‐time basis with practical exposure at their hospitals & state‐of‐the‐art simulation lab under the new education policy (NEEP), GOVT of India. Allied Health Science is in great demand as there are huge demand of candidates now in India owing to expansion happening in health sector post COVID 19.

Shalby is a chain of Multi-specialty tertiary care hospitals based out of Ahmedabad. It has combined bed strength of more than 700 beds with its multispecialty hospitals across Gujarat and Goa.

With the aforesaid investment, shareholding of MMDL in SGTPL is now increased to 99.33% from earlier 99.16%

Shalby is currently trading at Rs. 124.70, up by 0.35 points or 0.28% from its previous closing of Rs. 124.35 on the BSE.

The scrip opened at Rs. 123.00 and has touched a high and low of Rs. 128.25 and Rs. 123.00 respectively. So far 8348 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 167.95 on 09-Jan-2023 and a 52 week low of Rs. 95.10 on 23-Jun-2022.

Last one week high and low of the scrip stood at Rs. 130.10 and Rs. 123.00 respectively. The current market cap of the company is Rs. 1364.16 crore.

The promoters holding in the company stood at 74.12%, while Institutions and Non-Institutions held 4.03% and 21.85% respectively.

Shalby’s wholly owned Subsidiary -- Mars Medical Devices (MMDL) has further subscribed 3,00,000 equity shares of Singapore Dollar 1 each in Shalby Global Technologies, Singapore (SGTPL), and remitted funds for the same on March 16, 2023. SGTPL is a subsidiary of Mars Medical Devices and a Step‐down Subsidiary of the Company. With the aforesaid investment, shareholding of MMDL in SGTPL is now increased to 99.33% from earlier 99.16%.

Shalby is a chain of Multi-specialty tertiary care hospitals based out of Ahmedabad. It has combined bed strength of more than 700 beds with its multispecialty hospitals across Gujarat and Goa.

Quarterly Results

Rs.1.0000 per share(10%)Final Dividend

Final Dividend & Audited Results

Quarterly Results

Quarterly Results

Rs.1.0000 per share(10%)Final Dividend

Quarterly Results

Audited Results

Quarterly Results

SGTPL is a subsidiary of Mars Medical Devices and a step-down subsidiary of the company

Shalby’s wholly-owned subsidiary -- Mars Medical Devices (MMDL) has further subscribed 1.80 lakh equity shares of SGD 1 each in its subsidiary -- Shalby Global Technologies, Singapore (SGTPL), and remitted funds for the same on August 22, 2022. SGTPL is a subsidiary of Mars Medical Devices and a step-down subsidiary of the company. With the aforesaid investment, shareholding of MMDL in SGTPL is now increased to 98.99% from earlier 98.76%.

Shalby is a chain of Multi-specialty tertiary care hospitals based out of Ahmedabad. It has combined bed strength of more than 700 beds with its multispecialty hospitals across Gujarat and Goa.

With the aforesaid investment, shareholding of MMDL in SGTPL is now increased to 99.16% from earlier 98.99%

Shalby’s wholly-owned subsidiary -- Mars Medical Devices (MMDL) has further subscribed 2,00,000 equity shares of Singapore Dollar 1 each in MMDL’s Subsidiary - Shalby Global Technologies Pte., Singapore (SGTPL), and remitted funds for the same on December 1, 2022. SGTPL is a subsidiary of Mars Medical Devices and a Step-down Subsidiary of the Company. With the aforesaid investment, shareholding of MMDL in SGTPL is now increased to 99.16% from earlier 98.99%.

Shalby is a chain of Multi-specialty tertiary care hospitals based out of Ahmedabad. It has combined bed strength of more than 700 beds with its multispecialty hospitals across Gujarat and Goa.

Total consolidated income of the company increased by 25.01% to Rs 206.50 crore for Q3FY23

Shalby has reported results for third quarter ended December 31, 2022.

The company has reported rise of 52.04% in its net profit at Rs 19.20 crore for Q3FY23 as compared to Rs 12.63 crore for the corresponding quarter previous year. Total income of the company increased by 17.45% to Rs 179.77 crore for the quarter as compared to Rs 153.07 crore for the same quarter in the previous year.

On the consolidated basis, the company has reported rise of 18.28% in its net profit at Rs 15.28 crore for Q3FY23 as compared to Rs 12.92 crore for the same quarter in the previous year. Total income of the company increased by 25.01% to Rs 206.50 crore for the quarter under review as compared to Rs 165.19 crore for the same quarter in the previous year.

SOCE Gwalior is a state- of-the-art orthopedic centre that will provide comprehensive orthopedic services under one roof

Shalby has launched 14th hospital with the inauguration of SOCE – Shalby Orthopedics Centre of Excellence in Gwalior (SOCE).  SOCE Gwalior is a state‐ of‐the‐art orthopedic centre that will provide comprehensive orthopedic services under one roof. With this, people of the region will get best‐in‐class treatment for orthopedic disorders at their own doorstep and will not need to travel large distances to bigger cities.

Shalby is a chain of Multi-specialty tertiary care hospitals based out of Ahmedabad. It has combined bed strength of more than 700 beds with its multispecialty hospitals across Gujarat and Goa.

The board of directors at its meeting held on February 06, 2023 has approved the same

Shalby’s wholly owned subsidiary -- Vrundavan Shalby Hospitals (VSHL) has received approval from board of directors to start its business operations. The said subsidiary is now treated as ‘a going Concern’. The board of directors at its meeting held on February 06, 2023 has approved the same. 

Shalby is a chain of Multi-specialty tertiary care hospitals based out of Ahmedabad. It has combined bed strength of more than 700 beds with its multispecialty hospitals across Gujarat and Goa.

Now, SGT can import the said implants and medical devices from USA and sell in Indonesia

Shalby’s step‐down subsidiary -- Shalby Global Technologies, Singapore (SGT) has received a regulatory approval to market and sell Knee Implants, Hip Systems, Knee and Hip Instruments, etc. by Ministry of Health, Indonesia. Now, SGT can import the said implants and medical devices from USA and sell in Indonesia.

This development is fully in line with company’s stated strategy to grow company’s Orthopaedic implant business and establish footprint in the Medical device market internationally. This is a big milestone achieved by the Shalby group in its journey to serve many more international patients. The synergies between the businesses are compelling and will bring in immediate benefits of sourcing US FDA approved quality implants into Indonesia through company’s distribution channels. Shalby has performed more than 1,44,000 joint replacement surgeries so far and continues to be the leader in India and globally in terms of the volume of surgeries performed annually.

Shalby is a chain of Multi-specialty tertiary care hospitals based out of Ahmedabad. It has combined bed strength of more than 700 beds with its multispecialty hospitals across Gujarat and Goa.

This will be a customized program for healthcare professionals aspiring to become CXOs in the Hospital Industry

Shalby Academy, the healthcare education division of Shalby, has signed a memorandum of understanding (MoU) with the Indian Institute of Public Health University (IIPH), Gandhinagar, Gujarat to jointly develop and run a one‐year Advance Management Program in Hospital Leadership, for capacity building of Healthcare Professionals in the India and abroad using the LMS platform of the University & Shalby Academy.

The Program will be offered via online and campus immersion modes with a focus on emerging challenges in hospital & healthcare management leveraging the strength of both parties. This will be a customized program for healthcare professionals aspiring to become CXOs in the Hospital Industry.

Shalby is a chain of Multi-specialty tertiary care hospitals based out of Ahmedabad. It has combined bed strength of more than 700 beds with its multispecialty hospitals across Gujarat and Goa.

The company has signed MoU to jointly develop various vocational undergraduate & post Graduate courses in allied health science

Shalby’s healthcare education division -- Shalby Academy has signed Memorandum of understanding (MoU) with Silver Oak University, Ahmedabad to jointly develop various vocational undergraduate & post Graduate courses in allied health science like Radio imaging, Operation Theater & Medical Laboratory Technology.

As a skill knowledge partner, Shalby Academy will conduct these programs on a full‐time basis with practical exposure at their hospitals & state‐of‐the‐art simulation lab under the new education policy (NEEP), GOVT of India. Allied Health Science is in great demand as there are huge demand of candidates now in India owing to expansion happening in health sector post COVID 19.

Shalby is a chain of Multi-specialty tertiary care hospitals based out of Ahmedabad. It has combined bed strength of more than 700 beds with its multispecialty hospitals across Gujarat and Goa.

With the aforesaid investment, shareholding of MMDL in SGTPL is now increased to 99.33% from earlier 99.16%

Shalby’s wholly owned Subsidiary -- Mars Medical Devices (MMDL) has further subscribed 3,00,000 equity shares of Singapore Dollar 1 each in Shalby Global Technologies, Singapore (SGTPL), and remitted funds for the same on March 16, 2023. SGTPL is a subsidiary of Mars Medical Devices and a Step‐down Subsidiary of the Company. With the aforesaid investment, shareholding of MMDL in SGTPL is now increased to 99.33% from earlier 99.16%.

Shalby is a chain of Multi-specialty tertiary care hospitals based out of Ahmedabad. It has combined bed strength of more than 700 beds with its multispecialty hospitals across Gujarat and Goa.